Drugs For Benign Prostatic hypertrophy Global Market Report 2024

Description

“Drugs For Benign Prostatic hypertrophy Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The drugs for benign prostatic hypertrophy market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
Companies Mentioned: Allergan Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.

The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed during the historical period can be attributed to several factors, including the aging population, heightened awareness of benign prostatic hypertrophy, advancements in drug therapies, and improved access to healthcare services. These factors have contributed to the historical growth of treatments for this condition.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of emerging markets, the development of new drugs, heightened awareness and education about benign prostatic hypertrophy, and regulatory approvals for treatments. Prominent trends in the forecast period encompass the adoption of minimally invasive treatments, the practice of personalized medicine, the use of combination therapies, a focus on patient-centered care, the integration of telemedicine and digital health solutions, and ongoing research and development efforts in the field.

The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.

The growing prevalence of prostate diseases is expected to drive the future growth of the drugs for benign prostatic hypertrophy market. Prostate diseases encompass various medical conditions that impact the prostate gland, a male reproductive organ situated just below the bladder. Drugs for benign prostatic hypertrophy (BPH) play a critical role in managing and mitigating urinary symptoms associated with prostate diseases. These medications provide relief by reducing the enlargement of the prostate gland and improving urine flow. For instance, a report from the Harvard Medical School, a US-based medical institution, in February 2021, revealed that by the age of 60, 50% of men will experience prostate enlargement, and this proportion increases to 90% by the age of 85. Therefore, the increased prevalence of prostate diseases is propelling the growth of the drugs for benign prostatic hypertrophy market.

The increasing adoption of minimally invasive surgeries, driven by technological advancements, is a factor restraining the growth of the Benign Prostatic Hyperplasia drugs market. Minimally invasive surgeries typically result in less pain and are often performed on an outpatient basis, negating the need for Benign Prostatic Hyperplasia drugs. This serves as a limitation on the market. Some of the minimally invasive surgical approaches used for Benign Prostatic Hyperplasia treatment include laparoscopic prostatectomy, transurethral microwave thermotherapy (TUMT), and transurethral needle ablation (TUNA).

The combination drugs are gaining prominence in the treatment of benign prostatic hypertrophy due to their enhanced effectiveness and disease progression prevention. Combination drugs incorporate two or more active pharmaceutical ingredients (APIs) within a single dosage form. These drugs reduce the risk of drug resistance, lead to fewer side effects, and have a lower treatment failure rate. For instance, Duodart, which combines dutasteride and tamsulosin hydrochloride, is increasingly prescribed for Benign Prostatic Hypertrophy treatment.

Major companies in the drugs for benign prostatic hypertrophy market are concentrating on the introduction of innovative medications like Entadfi to maximize their market revenue. Entadfi is a prescription medicine designed to address the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. For example, in December 2021, Veru Inc., a US-based biotechnology company, obtained approval from the United States Food and Drug Administration (FDA) for Entadfi. This prescription medication is intended for the treatment of BPH symptoms in men with an enlarged prostate for a duration of up to 26 weeks. The approval of Entadfi was based on a randomized, double-blind, placebo-controlled phase 3 study that assessed the efficacy and safety of tadalafil in combination with finasteride in 696 men. Entadfi is provided in capsule form, containing a combination of finasteride 5mg and tadalafil 5mg, available in 30- or 90-count bottles.

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2023. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drugs for benign prostatic hypertrophy market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r9103

1. Executive Summary

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Drugs For Benign Prostatic hypertrophy Market Size and Growth

5.1. Global Drugs For Benign Prostatic hypertrophy Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Drugs For Benign Prostatic hypertrophy Market Segmentation

6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Alpha Blocker
5-alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Other Types
6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Other End-Users

7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Drugs For Benign Prostatic hypertrophy Market

9.1. China Drugs For Benign Prostatic hypertrophy Market Overview
9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Drugs For Benign Prostatic hypertrophy Market

10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Drugs For Benign Prostatic hypertrophy Market

11.1. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Drugs For Benign Prostatic hypertrophy Market

12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Drugs For Benign Prostatic hypertrophy Market

13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Drugs For Benign Prostatic hypertrophy Market

14.1. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Drugs For Benign Prostatic hypertrophy Market

15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview
15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Drugs For Benign Prostatic hypertrophy Market

16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Drugs For Benign Prostatic hypertrophy Market

17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Drugs For Benign Prostatic hypertrophy Market

18.5. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Drugs For Benign Prostatic hypertrophy Market

19.9. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Drugs For Benign Prostatic hypertrophy Market

20.13. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

21.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview
21.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Drugs For Benign Prostatic hypertrophy Market

22.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Drugs For Benign Prostatic hypertrophy Market

23.1. North America Drugs For Benign Prostatic hypertrophy Market Overview
23.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Drugs For Benign Prostatic hypertrophy Market

24.1. USA Drugs For Benign Prostatic hypertrophy Market Overview
24.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Drugs For Benign Prostatic hypertrophy Market

25.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview
25.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Drugs For Benign Prostatic hypertrophy Market

26.1. South America Drugs For Benign Prostatic hypertrophy Market Overview
26.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Drugs For Benign Prostatic hypertrophy Market

27.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Drugs For Benign Prostatic hypertrophy Market

28.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview
28.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Drugs For Benign Prostatic hypertrophy Market

29.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview
29.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

30.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape
30.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles
- 30.2.1. Allergan Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Astellas Pharma Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Boehringer Ingelheim International GmbH
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. GlaxoSmithKline plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Teva Pharmaceutical Industries Limited
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking

32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

34. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis

34.1 Drugs For Benign Prostatic hypertrophy Market In 2028 - Countries Offering Most New Opportunities
34.2 Drugs For Benign Prostatic hypertrophy Market In 2028 - Segments Offering Most New Opportunities
34.3 Drugs For Benign Prostatic hypertrophy Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer